Is FDA-approved HRT safer than BHRT?

Whether FDA-approved HRT is a more appropriate option than compounded BHRT depends on individual health factors that cannot be fully assessed through website content alone. That said, current clinical guidelines note meaningful differences in how each category is regulated and tested.

Why FDA-approved HRT has a stronger regulatory basis

According to current NAMS guidelines, FDA-approved hormone therapy products undergo rigorous testing for purity, potency, stability, and pharmacokinetics before reaching patients. Per FDA-approved prescribing information, this testing process means that dose and absorption are validated across production batches, supporting more predictable clinical outcomes.

According to ACOG, many FDA-approved hormone therapy formulations contain bioidentical hormones — including estradiol and micronized progesterone. Both FDA-approved products (such as estradiol and micronized progesterone) and compounded preparations may contain bioidentical hormones. The term does not indicate superiority of one category over another.

Where compounded BHRT fits in

Per published clinical guidelines, compounded BHRT may be considered when a patient requires a dose, strength, route, or combination that is not available in any commercially approved product. Reputable compounding pharmacies can produce individualized formulations, and some patients do well on them under close clinical supervision.

Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs.

According to the WHI long-term follow-up data and per published clinical guidelines, hormone levels in compounded preparations may vary across batches, which can affect symptom management and monitoring. This underscores the importance of regular follow-up with a prescriber when using compounded formulations.

Key factors a prescriber considers

• Dose consistency: Per FDA-approved prescribing information, approved products have validated dosing across batches, which supports predictable clinical monitoring.
• Type of hormone: According to current NAMS guidelines, bioidentical estradiol and micronized progesterone are associated with a more favorable tolerability profile compared with synthetic progestins.
• Route of administration: Per the Endocrine Society, transdermal estrogen formulations are associated with a lower venous thromboembolism risk compared with oral estrogen, regardless of whether the product is FDA-approved or compounded.
• Ongoing monitoring: According to ACOG, regular clinical follow-up improves outcomes with either category of hormone therapy.

Bottom line

When a commercially available FDA-approved product meets a patient's clinical needs, current guidelines support considering it as the first option, given the regulatory oversight and validated dosing it provides. Compounded BHRT, when prepared by a skilled pharmacy, may be a reasonable alternative when a personalized formulation is clinically necessary and no approved equivalent exists.

Whether HRT is appropriate depends on individual health factors. A prescriber should determine the best approach based on a patient's complete medical history.